Search | OpenScholar

Search results

356 results found

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95.

Publication: Journal Article

Smith, KM, E Eyal, D Weintraub, and Adagio Investigators. 2015. “Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability. JAMA Neurol 2015;72:88-95.”. JAMA Neurol.

Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evid Based Med 2015;20:17.

Publication: Journal Article

Hauser, RA. 2015. “Initial Choice of Medication Has Little Effect on Short-Term or Long-Term Outcome for Most Patients With Parkinson’s Disease. Evid Based Med 2015;20:17.”. Evid Based Med.

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.

Publication: Journal Article

Poewe, W, RA Hauser, and A Lang. 2015. “Effects of Rasagiline on the Progression of Nonmotor Scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.”. Mov Disord.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.

Publication: Journal Article

Bega, D, S Kim, Y Zhang, J Elm, J Schneider, R Hauser, A Fraser, and T Simuni. 2015. “Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.”. J Parkinsons Dis.

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:268-75.

Publication: Journal Article

Low, PA, D Robertson, S Gilman, H Kaufmann, W Singer, I Biaggioni, R Freeman, et al. 2014. “Efficacy and Safety of Rifampicin for Multiple System Atrophy: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol 2014;13:268-75.”. Lancet Neurol.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.

Publication: Journal Article

Hauser, RA, MF Gordon, Y Mizuno, W Poewe, P Barone, AH Schapira, O Rascol, C Debieuvre, and M Fradorf. 2014. “Minimal Clinically Important Difference in Parkinson’s Disease As Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.”. Parkinsons Dis.

Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80.

Publication: Journal Article

Goldman, SM, F Kamel, GW Ross, SA Jewell, C Marras, JA Hoppin, DM Umbach, et al. 2014. “Peptidoglycan Recognition Protein Genes and Risk of Parkinson’s Disease. Mov Disord 2014;29:1171-80.”. Mov Disord.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13:767-76.

Publication: Journal Article

Hauser, RA, CW Olanow, KD Kieburtz, E Pourcher, A Docu-Axelerad, M Lew, O Kozyolkin, et al. 2014. “Tozadenant (SYN115) in Patients With Parkinson’s Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol 2014;13:767-76.”. Lancet Neurol.

Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.

Publication: Journal Article

Bajaj, N, RA Hauser, J Seibyl, A Kupsch, M Plotkin, C Chen, and ID Grachev. 2014. “Association Between Hoehn and Yahr, Mini-Mental State Examination, Age, and Clinical Syndrome Predominance and Diagnostic Effectiveness of Ioflupane I 123 Injection (DaTSCAN™) in Subjects With Clinically Uncertain Parkinsonian Syndromes.”. Alzheimers Res Ther.

Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-6.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, RA Hauser, JM Miyasaki, AP Nicholas, W Poewe, et al. 2013. “Which Dyskinesia Scale Best Detects Treatment Response? Mov Disord 2013;28:341-6.”. Mov Disord.